Abstract
Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Current Pharmaceutical Design
Title:Antiepileptic Treatments in Developing Countries
Volume: 23 Issue: 37
Author(s): Jeremy Jost*, Athanase Millogo and Pierre-Marie Preux
Affiliation:
- INSERM, Univ. Limoges, CHU Limoges, UMR_S 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, CNRS FR 3503 GEIST, F-87000 Limoges,France
Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Abstract: Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Export Options
About this article
Cite this article as:
Jost Jeremy *, Millogo Athanase and Preux Pierre-Marie, Antiepileptic Treatments in Developing Countries, Current Pharmaceutical Design 2017; 23 (37) . https://dx.doi.org/10.2174/1381612823666170809103202
DOI https://dx.doi.org/10.2174/1381612823666170809103202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology The Patch Clamp Technique in Ion Channel Research
Current Pharmaceutical Biotechnology Systematic Comparison of the Performance of Different 2D and 3D Ligand-Based Virtual Screening Methodologies to Discover Anticonvulsant Drugs
Combinatorial Chemistry & High Throughput Screening The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology Mathematical Modelling and Feature Extraction for Probing Crucial Changes Associated with Alzheimers Disease
Current Medical Imaging Computational Protein-Protein Docking Reveals the Therapeutic Potential of Kunitz-type Venom against hKv1.2 Binding Sites
CNS & Neurological Disorders - Drug Targets Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery High-Throughput Screening of Neuronal Cl- Channels: Why and How?
Current Neuropharmacology Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Pharmacological Characterisation and Modulation of Neuroplasticity in Humans
Current Neuropharmacology Curcumin Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting NLRP1-dependent Neuronal Pyroptosis
Current Neurovascular Research Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders
Current Drug Targets Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience Acute Symptomatic Seizures in Geriatric Patients with Multiple Risk Factors - A Diagnostic Challenge
Current Aging Science